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In the past, it was rare to see patients with cystic fibrosis (CF) on adult inpatient services as 
patients’ lifespans were limited. In 1955, most children with CF were not expected to live long 
enough to attend elementary school. Today the predicted median survival is in the early 40’s. 
This is largely due to the care provided through the national network of CF Foundation-
accredited centers. This is a nationwide network of more than 110 centers where teams of experts 
in the care and management of CF treat people living with this disease. The CF Foundation’s 
Care Center Network has been cited by the National Institutes of Health as a model of effective 
and efficient health care delivery for a chronic disease. Each center undergoes regular review of 
practices by the Foundation Center Committee prior to accreditation and funding. The national 
registry of the Cystic Fibrosis Foundation (cff.org), a registry that collects information from 
more than 27,000 people with CF who have agreed to share their medical data for research 
purposes, expects that the total number of adult patients will soon exceed the total number of 
patients younger than 18. Most CF patients receive care from CF specialty centers. CF specialty 
centers work in collaboration with local medical providers to deliver coordinated care for these 
complicated patients. 
While pediatric providers have historically cared for this population’s needs throughout their 
shortened lives, CF patients now rarely succumb to this disease in childhood and increasingly 
seek care from adult providers. We now expect to see CF patients for decades after they turn 18. 
It is for this reason adult Hospitalists should become proficient in recognizing the needs and 
providing for the management of the hospitalized CF patient. The existing literature puts forth 
well-reviewed and extensively studied clinical practice guidelines for the care of a hospitalized 
patient with symptoms of a Cystic Fibrosis pulmonary exacerbation. These are consensus reports 
based on the accumulation of evidence in Cochrane reviews as well as the cumulative experience 
of a number of experts representing the larger CF care community. The purpose of this series of 
articles is to summarize this body of work for the generalist and point out the resources available 
to the providers at the bedside. It will initially cover the basics of an admission, and in 
subsequent installments will expand the discussion of care to include the complications 
Hospitalists see in caring for these patients. Below is an outline of the basic evaluation and 
management of a patient presenting with a pulmonary exacerbation: 
1. Recognition of need for hospitalization  
a. Symptoms-pulmonary (GI symptoms predominate when patient presents 
with DIOS*)  
i. Hemoptysis 
ii. Cough 
iii. Changes in the character of the sputum 
iv. Chest pain 
v. Anorexia/vomiting 
b. Signs  
i. Increased work of breathing 
ii. Fever 
iii. Weight loss 
iv. Changes on pulmonary exam (abdominal exam) 
c. Data  
i. Hypoxemia 
ii. Decline in lung volumes as measured by pulmonary function 
testing (PFT) or spirometry 
iii. Change in CXR or other imaging 
iv. Leukocytosis 
v. Change in microbial inhabitants of the sputum 
2. Rationale of treatment  
a. Based on pathophysiology of the disease (abnormal mucus) 
b. Guided by microbiology of airway  
i. Chronic colonizers 
ii. Viral infections 
iii. Mycobacterium 
iv. ABPA (allergic/inflammatory response to aspergillosis) 
c. Measured by;  
i. Symptom resolution 
ii. Recovery of lung volumes 
3. Setting  
a. Home 
b. Hospital (specific floor) 
  
 Special considerations 
  
a. IV access 
b. Infection control (private room and shower, rounding on patients) 
c. Exercise (DVT prophylaxis and another form of chest physiotherapy) 
d. Access to calories (extra food, enzyme replacement) 
e. IV fluids 
f. Pregnancy testing 
  
1. Therapies  
a. Oxygen 
b. Antibiotics 
c. Airway clearance therapies 
d. Nutrition 
e. Bowel program 
2. Complications  
a. Hemoptysis 
  
3. Pneumothorax 
4.    
a. Pain 
b. Hepatic, renal and neurologic disturbances 
c. Nausea, vomiting, diarrhea, and/or steatorrhea 
d. CF-related diabetes 
e. Rectal prolapse 
f. Urinary incontinence 
5. Monitoring/surveillance  
a. Weights 
b. Pulse oximetry 
c. Labs 
d. Culture data 
e. Blood sugars 
f. Imaging 
g. Immunizations and preventive care 
6. Collaboration/consultation  
a. CF team, (CF doctor, CF dietician, CF nurse, CF respiratory therapist, CF social 
work, CF psychologist, pulmonologist and intensive care specialists) 
b. GI, ENT, Endocrinology 
7. Transplant 
8. End-of-life care 
*Patients with cystic fibrosis can present for acute care for other reasons unrelated to lung 
disease, including; the development of DIOS, pancreatitis in the pancreatic-sufficient patient, 
pregnancy management, infertility workup and treatment, complications of cirrhosis as a result 
of CF-liver disease, and complications of CF-related diabetes. 
PATHOPHYSIOLOGY 
For an detailed discussion about the pathophysiology of cystic fibrosis, I will refer to the 
resource information. In brief, cystic fibrosis is a complex genetic disease affecting many organs, 
although 80-90% of the mortality is a result of lung disease. Cystic fibrosis lung disease begins 
early in life and is a result of mutations in the CFTR (cystic fibrosis transmembrane conductance 
regulator) protein. CFTR functions as a chloride channel in epithelial membranes. Insufficiency 
of the protein leads to pathologic changes in organs that express CFTR. These include secretory 
epithelial cells of many organs including; sinuses, lungs, pancreas, liver, the reproductive tract 
and sweat glands in the skin. The most striking change occurs in the airway surface liquid. 
Electrolyte changes in the airway lead to the following complex interactions: 
1. Abnormal mucus resulting from dehydration of the airway surface liquid layer 
2. Impaired mucociliary clearance 
3. Colonization of the airway with multiple organisms ** 
4. An exaggerated, sustained, and extensive inflammatory response to the pathogens 
in the airway 
** Pseudomonas aeruginosa (Ps a.) has long been recognized as a significant pathogen in disease 
progression. Other recognized agents include methicillin-resistant Staphylococcus aureus 
(MRSA), Achromobacter species, Stenotrophomonas maltophilia, Burkholderia cepacia and non-
tuberculosis mycobacteria (NTM). Studies have shown that these strains lead to worsening 
symptoms and can speed the decline in lung function. 
PULMONARY EXACERBATION 
Recognizing the need for treatment is the first step in management of a pulmonary exacerbation. 
Most patients with cystic fibrosis can recognize a change in symptoms and will either present to 
the outpatient clinic with new complaints (increased cough, increased amount of sputum with 
thickening and difficulty in airway clearance, chest pain, dyspnea, fatigue, new oxygen need, 
etc.) or contact the Cystic Fibrosis Center to report changes from baseline. Physical examination 
and pulmonary function testing will often confirm an exacerbation of lung disease. Patients can 
be treated with an outpatient course of antibiotics if symptoms are not too severe; however, with 
more significant symptoms such as hemoptysis, weight loss, fevers, hypoxemia or failure to 
recover after a course of oral antibiotics, patients will require hospitalization. Treatment of a 
pulmonary exacerbation is largely based on three elements: antimicrobial treatment, aggressive 
airway clearance, and adequate nutrition. 
ANTIMICROBIAL TREATMENT 
As previously mentioned, treatment therapies are based on the pathophysiology of the disease 
and the presence of abnormal mucus in the airway. The microbiology of the airway also guides 
the choice of therapies. The airway in CF is often chronically colonized by more than one 
bacterial agent and is also susceptible to periodic infection by viral agents as well as 
Mycobacterial species. In addition, the CF airway can demonstrate the allergic/inflammatory 
response of ABPA (allergic bronchopulmonary aspergillosis). For this reason, sputum is 
generally collected at every clinic visit and at the onset of a hospitalization for culture and 
sensitivities. Generally, AFB is checked approximately every 6-12 months and total IgE is 
monitored yearly. If the patient is unable to expectorate a sample for culture, bronchoscopy 
should be considered. Choice of initial antibiotic therapy is based on the identity and sensitivities 
of the organisms known to be present in the airway until new culture data can be obtained. In 
addition, most CF care providers double cover Pseudomonas (use two different active agents 
against the bacterium). Trials with single antibiotics have not shown equal efficacy. There is 
insufficient evidence to recommend for the simultaneous use of inhaled and IV antibiotics; 
however it is frequently practiced. There are currently no studies which define the optimal 
duration of antibiotics for a pulmonary exacerbation of cystic fibrosis. The practice is generally 
to let symptoms and lung volume measurements guide duration of therapy. 
Patients with Ps a. and strains of NTM are frequently on chronic oral antibiotic treatment. In 
general, these agents should not be discontinued during a hospitalization but continued along 
with appropriate IV antibiotics. CF care center physicians should provide assistance with choice 
of antimicrobial agents. Pharmacists at CF centers also play a crucial role in the care of these 
patients. At our center we ask for pharmacy dosing assistance to achieve appropriate dosing of 
aminoglycosides and vancomycin. 
Access for IV antibiotics may require the placement of a PICC line in those without an existing 
port. Patients with cystic fibrosis should be housed on a hospital floor where staff members are 
experienced in the care of these patients. This includes attention to infection control procedures, 
private rooms and showers, opportunities for exercise, consistent care of PICC lines and ports, 
access to supplemental nutrition, a knowledgeable team of respiratory therapists, and a 
supportive environment of staff familiar with this chronic illness. 
Recently, new infection and control guidelines have been drafted by the Cystic Fibrosis 
Foundation. The latest medical data show that the risk of spreading destructive bacteria among 
people with CF is greater than was previously believed. New findings include evidence that 
strains of different bacteria, such as Pseudomonas aeruginosa, MRSA, and NTM, have been 
spread between people with CF. Research also suggests that the risk of some germs spreading 
through the air is greater than was previously known. For these reasons it is now standard of 
practice to gown and glove when entering a patient’s room to examine the patient or provide 
care. Masks are used when the patient has infections spread by respiratory droplets (i.e. 
influenza). This is especially important when traveling between multiple CF patients’ rooms. 
On June 20th, 2014 the Cystic Fibrosis Foundation announced that updated guidelines for 
infection prevention and control have been endorsed by the Society for Healthcare Epidemiology 
of America (SHEA) and the Association for Professionals in Infection Control and Epidemiology 
(APIC). The updated guidelines will be published online in Infection Control & Hospital 
Epidemiology, the official journal of SHEA, within the next several weeks. 
AIRWAY CLEARANCE THERAPY 
Along with systemic antibiotics, airway clearance or pulmonary toilet is critical to the recovery 
of the CF patient. This includes a “package” of treatments referred to as airway clearance therapy 
(ACT). The treatment consists of specific aerosolized medications combined with mechanical 
airway clearance. This treatment package has been specifically intended for the abnormal airway 
of a cystic fibrosis patient with impaired mucociliary clearance. (A component of reactive 
airways disease often exits as well). ACT begins with a bronchodilator, such as albuterol, 
followed by either a mucolytic or a mucous hydrator, Pulmozyme, and hypertonic saline (7% 
saline). During these inhaled treatments, patients use chest physiotherapies such as external high-
frequency chest compression (“the vest”) or airway oscillating techniques such as flutter, 
Acapella, Coronet, EZpap or IPPV. This mechanical clearance is cycled and interspersed with 
intermittent “huff-cough.” The purpose of these techniques is to stimulate clearance of mucus 
from the airway. These therapies are “stepped up” or intensified during the hospital stay with a 
goal of 4-5 treatments per day (the well CF patient may only do 2 treatments per day). A 
combination of ACT modalities is often used. Hospitalization may provide an opportunity for 
patients to be introduced to new forms of airway clearance therapy. The respiratory therapy 
department or hospital practice must also provide equipment cleaning or replacement of tubing, 
handsets and other “contaminated” equipment regularly to prevent further contamination and 
spread of infection. CF teams have respiratory therapists well-versed in ACT and management of 
equipment. A review of home and hospital ACT equipment maintenance and cleaning 
procedures should be performed with patients regularly. To assist in infection control, it is best 
that patients bring their own vest with them to each hospitalization to ensure proper fit. This also 
decreases the risk of transmission of infectious agents between patients who share equipment. It 
is only after airway clearance has been effectively completed that it is appropriate to deliver 
inhaled antibiotics to the airway. 
NUTRITION 
The CF Foundation has been collecting data from the accredited CF Centers for many years. 
There is strong evidence that lung health is best maintained by achieving and maintaining 
adequate nutrition in CF patients. Target BMI values have been determined for adult male and 
female patients in addition to children. Weight loss is directly associated with a decline in 
pulmonary function. Caloric needs far exceed that of a healthy young person (2-3 times), even 
during wellness. Caloric needs are even greater during illness. Extra calories compensate for 
malabsorption and meet the greater energy needs in pulmonary disease. Pancreatic enzymes are 
critical for those patients who have pancreatic insufficiency. Fat-soluble vitamin supplements 
(vitamins A, D, E, and K) are also needed due to poor absorption. Vitamin K may be deficient in 
those with hemoptysis and is used routinely in massive hemoptysis even before lab values 
confirm a deficiency. CF teams always have a dietician trained in the management of CF 
malnutrition. 
IMAGING: 
A two view chest x-ray does not consistently demonstrate detectable infiltrates. It is often not 
informative of a pulmonary exacerbation. This is due to several reasons, including: 
1. The extent of disease and resultant damage to the anatomy with extensive scar in 
the lungs which may obscure infiltrates. 
2. A chest film seems to have less “sensitivity” to a pulmonary exacerbation than 
lung volumes and patient-reported symptoms. 
3. The chronicity of bacterial colonization, which is often not localized to a 
particular part of the lung but is scattered throughout the anatomy. There may be 
many “small pneumonias.” 
4. CF disease is in the airway (bronchi, bronchiole) and the alveoli are the “innocent 
bystanders” of inflamed tissues of the airway. 
(For billing purposes, it is our practice to refer to pulmonary exacerbations as “broncho-
pneumonia” along with the terminology “pulmonary exacerbation of cystic fibrosis” to aid 
billing and coding personnel). 
Other imaging performed for CF patients include: a yearly abdominal ultrasound as a screen for 
hepatic and renal disease, periodic bone scans due to poor absorption of vitamin D and 
malnutrition associated with this disease, and CT scans of sinus and lungs. 
LABORATORY STUDIES: 
*General chemistry to include renal and liver panels 
*Complete blood count to evaluate for leukocytosis or anemia 
*Sputum culture labelled with “Cystic Fibrosis” and yearly AFB 
*Pregnancy testing in females 
* Testing for influenza may be indicated 
*To meet guidelines, patients may need additional testing such as vitamin levels, PT/INR, total 
IgE, Hgb A1C, GGTP 
Our next discussion article on CF will quiz the reader over the preceding information and point 
out “pearls” to remember. 
RESOURCES 
1. Cystic Fibrosis Adult Care: Consensus Conference Report. Yankaskas J, Marshall 
B, Sufian B, Simon R, Rodman D; Chest 2004;125;1-39 http://chestjournal.org 
2. Cystic Fibrosis Foundation http://cff.org 
3. Cystic fibrosis foundation-Care Center reporting; 
http://www.cff.org/CCNP/DataPurposeUsage/ 
4. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of 
Lung Health; Flume et al; American Journal of Respiratory And Critical Care 
Medicine 2007;176:957-969 
5. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations; 
Flume et al; American Journal of Respiratory and Critical Care Medicine 2009; 
180:802-808 
